North Carolina clinical research organization PPD got an early Christmas present with the completion of its $3.9 billion acquisition by private equity firms The Carlyle Group and Hellman & Friedman. Talks about the CRO acquisition began in earnest over the summer as the parties negotiated price. The deal reached to pay $33.25 per share cash […]
Cetero Research, the North Carolina clinical research organization that fell under a U.S. Food and Drug Administration probe this year for allegedly falsifying data, has made two new hires that should help the CRO maintain regulatory compliance. Michael Fillios is now chief administrative officer for the Cary, North Carolina company. David Coggin has been named […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
$3 million is not bad for three months work. PPD CEO Ray Hill has stepped down from the clinical research organization a week after PPD’s acquisition by The Carlyle Group and Hellman & Friedman was finalized. He departs with a $3 million severance package for running the company since September. But it could have been […]
Quintiles is expanding its reach in the Asia-Pacific region with the launch of Kun Tuo, a new contract research organization in China. The new CRO will serve pharmaceutical companies in China as well as multinational biopharma companies that have operations in the country. Kun Tuo will also tap the resources of Durham, North Carolina-based Quintiles, […]
The Carlyle Group and Hellman & Friedman have completed their $3.9 billion acquisition of PPD (NYSE:PPDI). The private equity firms announced the completion of the all-cash deal for the clinical research organization today. The close follows an approval vote from shareholders last week. At the Nov. 30 shareholders meeting at PPD’s Wilmington, North Carolina headquarters, […]
PPD (NYSE:PPDI), among the largest clinical research organizations in the industry, is on its way to becoming a private company. Shareholders voted to approve the $3.9 billion sale of the Wilmington, North Carolina-based CRO to private equity firms The Carlyle Group and Hellman & Friedman. PPD said that more than 96 percent of shares voting […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Any PPD (NYSE:PPDI) shareholders with something to say about the $3.9 billion sale of the clinical research organization will probably be making their way today to the coastal city of Wilmington, North Carolina. At PPD’s global headquarters, the CRO has scheduled a meeting for shareholders to vote whether to approve the sale to private equity […]
Following a flurry of Quintiles acquisitions, the pharmaceutical services company now has news of a sale. Quintiles has sold its minority stake in drug commercialization joint venture Invida six years after forming the Asia Pacific-focused company with two other strategic investors. Menarini Group, a private Italian pharmaceutical company, has acquired all of Singapore-based Invida. Financial […]
PPD (NYSE:PPDI) will have no other acquirers trying to top the $3.9 billion bid for the clinical research organization from private equity firms The Carlyle Group and Hellman & Friedman. Just one party entered into the same confidentiality agreements that Carlyle and H&F agreed to in order to begin acquisition talks with the CRO. But […]
The five-plus years of Cetero Research clinical data called into question by the U.S. Food and Drug Administration is being shortened by nearly nine months. The FDA in July disclosed an inquiry into the Cary, North Carolina clinical research organization that alleged Cetero workers falsified clinical trial documents and test results from April 1, 2005 […]
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Quintiles‘ M&A activity continues as the company announced it will acquire clinical research organization Advion BioServices — Quintiles’ third deal in the last week. Advion provides bioanalytical lab services that help pharmaceutical companies understand how a drug performs in the body. A definitive agreement to acquire the Ithaca, New York-based CRO was signed today. Financial […]
Days before PPD‘s (NYSE:PPDI) $3.9 billion sale to private equity was announced on October 3, the clinical research organization’s lead independent director, Ernest Mario, was busy trading e-mails and phone calls with The Carlyle Group in an effort to improve what had become a substantially reduced offer. Carlyle and Hellman & Friedman, the other private […]
Quintiles announced its second strategic acquisition of the day, a deal to buy late phase pharmaceutical research firm Outcome Sciences. Durham, North Carolina-based Quintiles earlier today announced acquisitions of pharmaceutical marketing and commercialization firm VCG & Associates and its subsidiary VCG BIO. Outcome Sciences, based in Cambridge, Massachusetts, conducts late-stage and post-marketing research on drugs. […]
Quintiles has acquired pharmaceutical commercialization and marketing firm VCG & Associates and its subsidiary, VCG Bio, in a move to bolster the company’s drug capabilities to bring new drugs to market. Durham, North Carolina based Quintiles, already the largest clinical research organization or CRO, has been taking steps to build its drug commercialization offerings in […]
Clinical research organization Novella Clinical hopes Cathy Tyner can translate the clinical oversight work she pioneered at Quintiles into a comprehensive offering for Novella and a competitive edge against other mid-sized CROs. Tyner was been hired by Durham, North Carolina-based Novella as executive director, oversight group management. In that role, she will oversee third parties […]